Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Other financing activities (2018 - 2025)

TELA Bio has reported Other financing activities over the past 6 years, most recently at $3.4 million for Q4 2025.

  • Quarterly results put Other financing activities at $3.4 million for Q4 2025, up 30381.82% from a year ago — trailing twelve months through Dec 2025 was $3.6 million (up 863.14% YoY), and the annual figure for FY2025 was $3.6 million, up 863.14%.
  • Other financing activities for Q4 2025 was $3.4 million at TELA Bio, up from $21000.0 in the prior quarter.
  • Over the last five years, Other financing activities for TELA hit a ceiling of $3.4 million in Q4 2025 and a floor of $1000.0 in Q2 2023.
  • Median Other financing activities over the past 4 years was $19000.0 (2024), compared with a mean of $504866.7.
  • Biggest five-year swings in Other financing activities: plummeted 99.97% in 2023 and later soared 30381.82% in 2025.
  • TELA Bio's Other financing activities stood at $4000.0 in 2022, then changed by 0.0% to $4000.0 in 2023, then surged by 175.0% to $11000.0 in 2024, then soared by 30381.82% to $3.4 million in 2025.
  • The last three reported values for Other financing activities were $3.4 million (Q4 2025), $21000.0 (Q3 2025), and $3000.0 (Q2 2025) per Business Quant data.